Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 The Market Element LLC, a ... alliance with Designing Gig LLC to provide website design, ... , “Forging this alliance with Designing Gig represents a ... extend a comprehensive, end-to-end, digital solution for our clients, ... said Chuck Miller, president of The Market Element. “For ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies and ... of Public Health and New Haven Farms to capture ... project. The goal of the study was to evaluate ... access to fresh produce and nutrition education on food ... blood pressure, diabetes and weight gain. Patients completed an ...
(Date:3/25/2015)... 2015 Optimal Research, LLC has been nominated ... Award "Best Clinical Site or Trial Network". ... been selected as a nominee in this ViE award ... Recommended" distinction in 2014. The ViE awards were created ... and positive contributions of companies and individuals in the ...
Breaking Biology Technology:The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... (Amex: NBS ),which is pioneering the pre-disease collection, ... medical need, today announced that,Denis Rodgerson, Ph.D., NeoStem,s Director ... Nevada Las Vegas campus this evening. In,October 2007, NeoStem ... collection centers into Las Vegas, the first in the ...
... Nordisk, a,healthcare company with an 85-year history of ... to expand its U.S. headquarters in,Princeton to accommodate ... company,has experienced a 150 percent increase in employees ... have the capacity for more than 400 employees ...
... Cellvizio Inc., a leader in in,vivo cellular imaging, ... its Cellvizio(R) GI technology will be conducted March ... Medicine,s Eighth,Annual Gastroenterology and Hepatology Viva La Vida ... of Paris-based Mauna Kea,Technologies and develops and markets ...
Cached Biology Technology:NeoStem's Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus 2NeoStem's Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus 3Novo Nordisk Expands U.S. Headquarters in New Jersey 2Novo Nordisk Expands U.S. Headquarters in New Jersey 3First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference 2
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... March 4, 2009 The incidence of pneumothorax (PTX), or ... trauma has been reported to range from 13 50 ... In people, PTX is reported to be the most ... Thoracic ultrasound has been infrequently used as a non-invasive, point-of-care ...
... not lower, costs and very large reductions in greenhouse ... the key take-home messages from a series of expert ... Future (RBAEF)" in a special issue of Biofuels, ... that the collection, which includes a comparative analysis of ...
... March 3, 2009 "Undesirable" evolution in fish ... dwindle -- can actually be reversed in a few ... fishing, according to groundbreaking new research published today by ... Royal Society B . Intensive harvesting of the ...
Cached Biology News:Novel veterinary procedure detecting life-threatening injuries touted 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 2Cellulosic biofuel technology will generate low-cost green fuel, says major study 3'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 2'Undesirable' evolution can be reversed in fish, Stony Brook University scientists show 3
...
... assay (ELISA) test kits are qualitative one-step ... detection of drugs and/or their metabolites in ... forensic use only. It is recommended that ... quantitative method such as GC/MS. The ...
96 Well Base Plate...
... Inhibitor is a recombinant human protein produced in ... neutral pancreatic RNase A type enzymes. The ... binds RNases in a 1:1 ratio. The enzyme ... many tissues and cell types. Addition of the ...
Biology Products: